A-446
Probe criteria
| Inhibitor/agonist potency: goal is < 100 nM (IC50, Kd) | Surpasses criterion: GAC (GLS) Enzyme activity assay: IC50 = 31 nM |
| Selectivity within target family: > 30-fold | GLS2 Enzyme activity assay: : IC50 > 30 µM (>1000-fold selectivity) |
| Selectivity outside target family | Probe selectivity observed in Proteome Integral Stability Assay. Closest off-targets in Cerep binding assay at 10 μM (percent inhibition of control specific binding): ADORA3 ( agonist radioligand) 76.6 %, CHRM1 (antagonist radioligand) 92.6 %, CHRM2 (antagonist radioligand) 71.5 % Clean PDSP scan data (44 targets) at 10 µM except for HTR1D (Ki = 6453.57 nM) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: CTG assay in A549 cells IC50 = 11 nM |
| Control compound (100 times less potent than the probe) | A-426: GAC (GLS) Enzyme activity assay: : IC50 > 30 µM (> 100-fold less active); GLS2 Enzyme activity assay: : IC50 > 30 µM |